Global initiative of quality assurance within the framework of the security of the cytotoxic circuit;Démarche globale d'assurance qualité dans le cadre de la sécurisation du circuit des cytotoxiques

Journal de Pharmacie Clinique

Volumn 28, Issue 4, 2009, Pages 199-206

  Hippy Muller, C ^a   Danicourt Barrier, F ^a   Hochart, S ^a   Perrinet, M ^a   Horrent, S ^a   Resibois, J P ^a   Decaudin, B ^a,b   Odou, P ^a,b  

^a Centre Hospitalier de Dunkerque   (France)

^b FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

Author keywords

Assurance; Circuit; Cytotoxic; Quality; Security

Indexed keywords

ANTIDOTE; BEVACIZUMAB; BLEOMYCIN; BUSULFAN; CAPECITABINE; CARBOPLATIN; CARBOPLATINE; CARMUSTINE; CHLORAMBUCIL; CISPLATIN; CISPLATINE; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DACARBAZINE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOFOS; FARMORUBICINE; FLUOROURACIL; FLUOROURACILE; FOTEMUSTINE; GEMCITABINE; HYDROXYUREA; IFOSFAMIDE; IRINOTECAN; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PENTOSTATIN; RALTITREXED; RAZOXANE; RITUXIMAB; TEMOZOLOMIDE; TIOGUANINE; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE SULFATE; VINCRISTINE; VINDESINE;

ARTICLE; DRUG CONTAMINATION; DRUG SAFETY; EXTRAVASATION; HEALTH SERVICE; HOSPITAL DEPARTMENT; MEDICAL AUDIT; MEDICAL EDUCATION; MEDICAL INSTRUMENTATION; ORGANIZATION AND MANAGEMENT; PHARMACY; QUALITY CONTROL; RISK ASSESSMENT; TOTAL QUALITY MANAGEMENT;

EID: 76049113981     PISSN: 02911981     EISSN: None     Source Type: Journal    
DOI: 10.1684/jpc.2009.0131     Document Type: Article

References (11)

1. Mason HJ, Morton J, Arfitt SJ, Iqbal S, Jones K. Cytotoxic drug contamination on the outside of vials delivered to a hospital pharmacy. Ann Occup Hyg 2003; 47: 681-5.
2. Crauste-Manciet S, Sessink PJ, Ferrari S, Jomier JY, Brossard D. Environmental contamination with cytotoxic drugs in healthcare using positive air pressure isolators. Ann Occup Hyg 2005; 49: 619-28.
3. Hedmer M, Georgiadi A, Bremberg ER, Jönsson BA, Eksborg S. Surface contamination of cyclophosphamide packaging and surface contamination with antineoplastic drugs in a hospital pharmacy in Sweden. Ann Occup Hyg 2005; 49: 629-37.
4. Circulaire DPHM/DH no 678 du 3 mars 1987 relative à la manipulation des médicaments anticancéreux en milieu hospitalier.
5. er février 2001 établissant les règles particulières de prévention des risques cancérogènes, mutagènes ou toxiques pour la reproduction et modifiant le code du travail.
6. Recommandations pour la manipulation des médicaments cytotoxiques dans les établissements de soins. C.CLIN Sud-Ouest. 2002.
7. Attitude pratique en cas d'extravasation d'anticancéreux. Dossier du CNHIM, XXV, 4-5.
8. Afssaps. Les alertes sanitaires. Retrait de lots de thiosulfate de sodium 10 % - UFCH. 07/12/2006.
9. Langer SW, Jensen PB, Sehested M. Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries. Cardiovasc Toxicol 2007; 7: 151-3.
10. Reeves D. Management of anthracycline extravasation injuries. Ann Pharmacother 2007; 41: 1238-42.
11. CNIMH. Administration et manipulation des anticancéreux. Dossier 2001, Tome XXII; 1-2: 15-41.